All In Biotech

Drug Trial Radar · NCT07680140

Biomarker-Guided Antidepressant Selection

Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Aug 10, 2026

Primary completion

Sep 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Weill Medical College of Cornell UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Icahn School of Medicine at Mount Sinai; National Institute of Mental Health (NIMH)
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments. This study will investigate two alternative treatment options for people whose depression has not responded to standard treatments: repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, and ketamine, a fast-acting medication. It can be difficult to decide between these interventions in clinical practice, and selecting between them often comes down to patient preference and trial and error. This study is working to optimize the selection approach: using biological and behavioral markers to match each person to identify biomarkers that may predict response to rTMS or ketamine. Investigators believe that differences in how individuals respond to rTMS versus ketamine are partly explained by differences in how their brains are organized, and that these differences can be measured and used to guide intervention decisions. This is an early-stage pilot study designed to test whether this biomarker-based approach is practical and acceptable to patients. Investigators will evaluate how well a combination of brain imaging and clinical data can predict, at the individual level, who is likely to respond to rTMS versus ketamine. The ultimate goal is to develop a reliable, scalable tool that helps clinicians make faster and more informed intervention decisions, reducing the time people with treatment-resistant depression spend searching for an antidepressant that works.

Conditions

  • Depression - Major Depressive Disorder
  • Treatment-resistant Depression (TRD)
  • rTMS
  • Ketamine
  • fMRI

Interventions

  • TMSDevice

    rTMS will be administered as intermittent theta burst simulation (iTBS) delivered to the left dorsolateral prefrontal cortex with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly rTMS sessions).

  • KetamineDrug

    Ketamine is a dissociative anesthetic with rapid-acting antidepressant properties. It will be administered in 6 total sessions (3 days x 2 weeks), each comprising a single subanesthetic dose of ketamine (0.5 mg/kg) delivered intravenously over 40 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to 2-Week Post-Intervention Score in Hamilton Depression Rating Scale (HDRS) ScoreTime frame: Baseline to 2-weeks post-intervention

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Ichan School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Weill Cornell Medicine

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.